← Back to Search

Biologic Response Modifier

VIB1116 for Rheumatic Diseases

Phase 1
Waitlist Available
Research Sponsored by Viela Bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new drug called VIB1116 to see if it is safe and well-tolerated in adults with rheumatic diseases. Researchers are giving the drug in different amounts to find the best dose.

Eligible Conditions
  • Dendritic Cell-Mediated Rheumatic Diseases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: VIB1116Experimental Treatment1 Intervention
Single dose of VIB1116, SC or IV administration. Multiple doses of VIB1116, SC administration.
Group II: PlaceboPlacebo Group1 Intervention
Single dose of Placebo, SC or IV administration. Multiple doses of Placebo, SC administration.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VIB1116
2021
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

Viela BioLead Sponsor
12 Previous Clinical Trials
1,031 Total Patients Enrolled
Viela Bio (acquired by Horizon Therapeutics)Lead Sponsor
6 Previous Clinical Trials
873 Total Patients Enrolled
Suzy Hammel, MSHSStudy DirectorHorizon Therapeutics
~18 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top